云南白药：2025年上半年实现营业收入212.57亿元

Core Viewpoint - Yunnan Baiyao announced strong growth in its financial performance for the reporting period, overcoming external challenges and optimizing its business structure [1] Financial Performance - The company achieved operating revenue of 21.257 billion yuan, a year-on-year increase of 3.92% [1] - The net profit attributable to shareholders reached 3.633 billion yuan, up 13.93% from 3.189 billion yuan in the same period last year, marking a historical high [1] - The net profit excluding non-recurring items was 3.461 billion yuan, a 10.40% increase from 3.135 billion yuan year-on-year, also a historical high [1] - Operating cash flow net amount was 3.961 billion yuan, reflecting a growth of 21.45% compared to the previous year [1] - The weighted average return on equity was 9.09%, an increase of 1.16 percentage points year-on-year [1] - Basic earnings per share were 2.04 yuan, a 13.97% increase from the previous year [1] Business Structure and Asset Quality - The proportion of industrial revenue in total operating revenue increased to 40.01%, up 2.6 percentage points year-on-year [1] - Industrial revenue growth rate reached 11.13% [1] - The company maintained a solid asset structure, with total assets of 54.535 billion yuan and net assets attributable to shareholders of 40.407 billion yuan [1] - The asset-liability ratio stood at 25.91%, with cash and cash equivalents amounting to 11.294 billion yuan [1]